MedTrace Logo

HUC-MSC for Treatment of High-risk HPV Infection

NCT06610773 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-09-24

No results posted yet for this study

Summary

To evaluate the safety and initial effectiveness of human umbilical cord mesenchymal stem cells in HPV clearance.

Conditions

  • Human Papillomavirus Viruses
  • Mesenchymal Stem Cells

Interventions

BIOLOGICAL

hUC-MSCs

1×10\^6/Kg hUC-MSCs (suspended in 100 mL normal saline containing 5% albumin) are infused intravenously to patients at a controlled rate of 60-80 drops/min.

BIOLOGICAL

Saline+albumin

Normal saline containing 5% albumin had a similar suspension and appearance package to hUC-MSCs, but no MSCs

Sponsors & Collaborators

  • Shanghai East Hospital

    lead OTHER

Principal Investigators

  • Fang Li, M.D,.PH.D. · Shanghai East Hospital, Shanghai Tongji University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-01
Primary Completion
2025-09-10
Completion
2026-09-10

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06610773 on ClinicalTrials.gov